Table 2 Malaria and anaemia episodes and Mullen Scales of Early Learning (MSEL) scores by chemoprevention trial arm
From: Malaria illness mediated by anaemia lessens cognitive development in younger Ugandan children
Malaria episodes before 2 years of age | Malaria episodes 2–3 years of age | Anaemia episodes before 2 years of age | Anaemia episodes 2–3 years of age | MSEL composite at 2 years of age | MSEL composite at 3 years of age | |
|---|---|---|---|---|---|---|
RCT trial arm—HUU cohort | ||||||
No chemoprevention (placebo) | 8.68 (4.80) | 7.70 (4.07) | 7.95 (5.71) | 0.48 (0.77) | 76.08 (11.67) | 75.15 (11.31) |
Daily trimethoprim–sulfamethoxazole (TS) | 7.25 (4.74)* | 7.77 (3.82) | 7.06 (5.37) | 0.76 (0.95) | 73.32 (12.78) | 75.74 (13.74) |
Monthly sulfadoxine–pyrimethamine (SP) | 8.70 (4.85) | 8.19 (4.08) | 8.06 (5.48) | 0.51 (0.69) | 74.79 (11.46) | 76.13 (11.03) |
Monthly dihydroartemisinin–piperaquine (DP) | 4.76 (4.39)*** | 8.00 (3.83) | 5.24 (4.41)** | 0.49 (0.66) | 75.78 (12.24) | 77.04 (11.78) |
RCT trial arm—HEU cohort | ||||||
No chemoprevention (placebo) | 6.87 (5.09) | 6.94 (4.66) | 6.36 (6.31) | 0.70 (0.88) | 73.00 (12.39) | 74.06 (10.22) |
Daily trimethoprim–sulfamethoxazole (TS) | 2.59 (2.51)*** | 6.21 (4.49) | 4.83 (3.70) | 0.76 (0.74) | 75.56 (13.17) | 74.21 (9.90) |
Monthly sulfadoxine–pyrimethamine (SP) | 5.85 (4.25) | 6.27 (3.85) | 7.42 (6.02) | 0.65 (0.80) | 74.45 (12.19) | 70.73 (9.36) |
Monthly dihydroartemisinin–piperaquine (DP) | 2.74 (3.15)*** | 5.68 (3.77) | 4.88 (3.62) | 0.68 (0.80) | 74.45 (12.19) | 69.21 (10.43) |